



Sykes, R., Ang, D. T. Y. and Berry, C. (2023) Invasive coronary microvascular function assessment: pharmacological versus exercise testing. *Heart*, (doi: 10.1136/heartjnl-2023-322512).

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<https://eprints.gla.ac.uk/295134/>

Deposited on: 27 March 2023

Enlighten – Research publications by members of the University of Glasgow  
<https://eprints.gla.ac.uk>

1 **Invasive Coronary Microvascular Function Assessment: Pharmacological vs**  
2 **Exercise Testing**

3 **Authors:** Robert Sykes<sup>1,2</sup>, Daniel Ang<sup>1,2</sup>, Colin Berry<sup>1,2,3</sup>

4 **Institutional Affiliations:**

- 5 1. School of Cardiovascular and Metabolic Health, University of Glasgow, G12 8TA, UK.  
6 2. Department of Cardiology, The West of Scotland Regional Heart and Lung Centre, Golden  
7 Jubilee National Hospital, Agamemnon Street, Clydebank, G81 4DY, UK.  
8 3. Department of Cardiology, Queen Elizabeth University Hospital, Queen Elizabeth  
9 University Hospital, 1345 Govan Road, Govan, Glasgow, G51 4TF, UK.

10 **Corresponding Author:** Professor Colin Berry, School of Cardiovascular and Metabolic  
11 Health, University of Glasgow, G12 8TA, UK. Email: Colin.Berry@glasgow.ac.uk; Tel:  
12 +441413303325.

13 **Twitter:** @\_RobSykes @DanielTYAng @ColinBerryMD @UofGSCMH

14 **Contributors:** All authors contributed to the drafting and revision of the editorial.

15 **Funding:** Professor Berry is supported by a British Heart Foundation Centre of Research  
16 Excellence award (RE/18/6/34217), EPSRC (EP/N014642/1; EP/S030875/1) and UKRI  
17 (MR/S018905/1).

18 **Competing interests:** Professor Colin Berry is employed by The University of Glasgow, which  
19 employs CB, holds research and consultancy agreements with Abbot Vascular, AstraZeneca,

20 Coroventis, GSK, HeartFlow, Menarini, Neovasc, Novartis, Siemens Healthcare and  
21 ValoHealth. These companies had no involvement in this manuscript. The other authors do not  
22 have any potential conflicts of interest.

23 **Patient consent for publication:** Not applicable.

24 **Ethics approval:** Not applicable.

25 **Provenance and peer review:** Commissioned; internally peer-reviewed.

26 **Word count:** 684

27 **References:** 8

28 Coronary microvascular dysfunction is characterised by functional and/or structural  
29 abnormalities[1]. It is associated with acute and chronic coronary syndromes, heart failure,  
30 non-ischaemic cardiomyopathies and impaired prognosis[2–6]. Since the heart is a deep organ,  
31 safe and accurate assessment of coronary microvascular function is challenging. Myocardial  
32 ischaemia is a blood supply: demand problem (**Figure 1**). Most research into coronary  
33 microvascular dysfunction is focused on perturbations in blood supply. Few studies of  
34 myocardial metabolism, particularly during exercise, have been undertaken.

35 The mechanistic study by Noaman et al. [7] provides new insights. Twenty-four patients  
36 presenting with myocardial injury, infarction or ischaemia with no obstructive coronary artery  
37 disease (MINOCA or INOCA) underwent microcirculatory resistance and myocardial  
38 metabolic assessment at the time of invasive coronary angiography. Microvascular resistance  
39 was measured in the left anterior descending coronary artery using coronary thermodilution.  
40 Measurements were taken at rest (basal resistance) and during hyperaemia (index of  
41 microvascular resistance [IMR]) induced by intravenous adenosine infusion. These  
42 measurements were then repeated after a graded exercise regime using a table-mounted  
43 ergometer. The microvascular findings were paired with transcardiac metabolic biomarkers as  
44 measured by blood sampling from the aorta and coronary sinus.

45 When stratified according to pre-exercise IMR, patients with a high IMR versus a normal IMR  
46 demonstrated: persistently lower coronary blood flow, higher microvascular resistance, blunted  
47 oxygen extraction, and increased lactate uptake during exercise. Further, the high IMR group  
48 had elevated transcardiac gradients of NT-proBNP and troponin following exercise. These  
49 differences suggest divergent pathophysiological phenotypes, which may identify different  
50 vascular and metabolic targets for therapy.

## 51 **Pharmacological vs Exercise-Induced Hyperaemia**

52 Pharmacological hyperaemia is a reference method for assessing microvascular function during  
53 invasive coronary angiography. Exercise stress testing is an alternative approach, albeit with  
54 logistical considerations. Further, exercise and pharmacological stress testing have differential  
55 haemodynamic effects. For example, adenosine-mediated hyperaemia decreases diastolic  
56 blood pressure secondary to vasodilation, whereas exercise increases systolic and usually  
57 diastolic blood pressure.

58 Noaman et al. proposed peri-procedural physiological stress as a complementary approach to  
59 adenosine-mediated hyperaemia. This combined approach has the potential to provide  
60 additional information relating to the effects of physical exercise, including myocardial and  
61 microcirculatory autoregulation, and metabolic efficiency. This approach to stress testing in  
62 the cardiac catheter laboratory more closely mimics the physiological changes during daily  
63 activity. Noting the limitations of the modest sample size, most patients in this study  
64 experienced a paradoxical increase in microvascular resistance during exercise.

65 This study had limitations, notably the sample size and selected population. While the authors  
66 have highlighted logistical challenges in performing these studies, further research seems  
67 justified. Future studies should incorporate controls for exercise and metabolic assessments,  
68 even if non-invasive tests (e.g. cardiac MRI) were adopted. The next steps could include studies  
69 of the associations between coronary flow reserve (CFR) and metabolic changes during  
70 adenosine versus exercise-induced stress. Invasively measured CFR is an important tool for  
71 the diagnosis of microvascular angina, given the well-established associations between  
72 invasive CFR and non-invasive ischaemia tests, and prognosis.

### 73 **Application in clinical practice**

74 The study population was heterogeneous. The inclusion of patients with MINOCA but without  
75 comprehensive investigation, like intravascular imaging and cardiac MRI, introduces data  
76 gaps, including on coronary and myocardial pathology.

77 The advantage of peri-procedural exercise testing lies in its improved disease stratification. The  
78 authors propose a more precision-based approach targeting endothelium or metabolic  
79 pathways, depending on the results. This may link with disease modification through aerobic  
80 exercise training and increased nitric oxide production [8].

81 Exercise ergometry in the catheter laboratory introduces non-trivial logistical and time  
82 considerations. In this study, the mean exercise duration was 8.5 minutes, excluding equipment  
83 setup. These logistical considerations may limit diffusion to wider clinical practice. The  
84 patient's ability to exercise is also relevant and performance may vary greatly depending on  
85 motivation and co-morbidities. Safety is always a primary consideration. No procedure-related  
86 complications were reported, despite coronary instrumentation during exercise, which is  
87 commendable.

88 Nonetheless, controlled exercise stress testing in the catheter laboratory may be helpful in  
89 selected patient groups.

### 90 *Conclusions*

91 Exercise-induced hyperaemia using a table-mounted ergometer during invasive coronary  
92 angiography is feasible and enriches the understanding of the patient's microcirculation during  
93 physiological stress. This lends insights into future targets for stratified therapy.

94 **References**

95 1 Ford TJ, Yii E, Sidik N, *et al.* Ischemia and No Obstructive Coronary Artery Disease.  
96 *Circ Cardiovasc Interv* 2019;**12**:e008126. doi:10.1161/CIRCINTERVENTIONS.119.008126

97 2 Ford TJ, Stanley B, Good R, *et al.* Stratified Medical Therapy Using Invasive Coronary  
98 Function Testing in Angina: The CorMicA Trial. *J Am Coll Cardiol* 2018;**72**:2841–55.  
99 doi:10.1016/j.jacc.2018.09.006

100 3 Sykes R, Doherty D, Mangion K, *et al.* What an Interventionalist Needs to Know About  
101 MI With Non-obstructive Coronary Arteries. *Interv Cardiol Rev* 2021;**16**.

102 4 Maznyczka A, Carrick D, Oldroyd K, *et al.* Thermodilution-derived temperature  
103 recovery time: a novel predictor of microvascular reperfusion and prognosis after myocardial  
104 infarction. *EuroIntervention*. doi:10.4244/EIJ-D-19-00904

105 5 Rush CJ, Berry C, Oldroyd KG, *et al.* Prevalence of Coronary Artery Disease and  
106 Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection  
107 Fraction. *JAMA Cardiol* 2021;**6**:1130–43. doi:10.1001/jamacardio.2021.1825


108 6 Cecchi F, Olivotto I, Gistri R, *et al.* Coronary Microvascular Dysfunction and Prognosis  
109 in Hypertrophic Cardiomyopathy. *N Engl J Med* 2003;**349**:1027–35.  
110 doi:10.1056/NEJMoa025050

111 7 Noaman S, Kaye D, Nanayakkara S, *et al.* Haemodynamic and Metabolic Adaptations  
112 in Coronary Microvascular Disease. *Heart* 2023;**Accepted for Publication**.

113 8 Hambrecht R, Wolf A, Gielen S, *et al.* Effect of Exercise on Coronary Endothelial  
114 Function in Patients with Coronary Artery Disease. *N Engl J Med* 2000;**342**:454–60.  
115 doi:10.1056/NEJM200002173420702



116 **Figure 1. Differential aetiology of myocardial ischaemia.**



117 Eur Heart J, ehac643, <https://doi.org/10.1093/eurheartj/ehac643>